The use of pyrotinib in special populations must strictly follow the principle of individualized treatment, with a focus on dose adjustment, safety monitoring, and contraindications. As a prescription-only drug, it should be administered after professional evaluation by a physician and used in full compliance with medical advice; self-adjustment of the dosage regimen is strictly prohibited.
Precautions for Medication in Special Populations
1. Elderly Patients
Limited clinical data are available for this population. The dosage should be adjusted based on the patient’s hepatic and renal function, comorbidities, and overall physical condition.
Close monitoring for adverse drug reactions (e.g., diarrhea, abnormal liver function) is required. Dose reduction or temporary treatment suspension should be implemented if necessary.
2. Patients with Hepatic or Renal Impairment
Hepatic impairment: For patients with mild to moderate hepatic impairment, a reduced initial dose is recommended. The drug is contraindicated in patients with severe hepatic impairment. During treatment, regular monitoring of transaminase, bilirubin, and other relevant indicators is essential.
Renal impairment: No dose adjustment is needed for patients with mild to moderate renal impairment. Caution should be exercised when administering the drug to patients with severe renal impairment, accompanied by close clinical monitoring.
3. Pregnant and Lactating Women
Pregnant women: Animal studies have demonstrated that pyrotinib exhibits embryotoxicity. Therefore, its use is contraindicated during pregnancy. Women of childbearing potential must adopt effective contraceptive measures during treatment and after drug discontinuation.
Lactating women: Pyrotinib may be excreted in human milk. Breastfeeding should be suspended either during treatment or throughout the lactation period.
4. Pediatric and Adolescent Patients
Currently, data on the safety and efficacy of pyrotinib in individuals under 18 years of age are lacking. In principle, the use of this drug is not recommended for this population.
5. Other High-Risk Populations
For patients with severe underlying diseases (e.g., cardiac dysfunction, autoimmune disorders), the potential benefits and risks must be fully evaluated before deciding on treatment initiation.
Medication Safety Reminders
Conduct regular re-examinations of blood routine, hepatic and renal function, and cardiac function during treatment, and manage adverse reactions promptly.
Seek immediate medical attention if severe diarrhea, skin reactions, or dyspnea occur.
Avoid co-administration with potent CYP3A4 inhibitors or inducers to prevent drug-drug interactions that may affect efficacy or increase toxicity.
The dosage regimen should be dynamically adjusted according to the patient’s specific condition. Standardized treatment under the guidance of an oncology specialist is recommended.
